Holen Sie sich die Stockscreener-App
17.48
2.76%
0.47
Pharming Group N V Adr Aktie (PHAR) Neueste Nachrichten
Operating expenses (excl. COGS) of Pharming Group NV Sponsored ADR – LSX:A2QLQY - TradingView
Pharming Group (NASDAQ:PHAR) Stock Price Up 11%Time to Buy? - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap DownHere's Why - MarketBeat
Pharming Group (NASDAQ:PHAR) Sets New 12-Month HighStill a Buy? - MarketBeat
Wall Street Analysts Believe Pharming Group (PHAR) Could Rally 81.71%: Here's is How to Trade - MSN
Pharming Group (NASDAQ:PHAR) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Up 8.6%Time to Buy? - MarketBeat
Earnings Estimates Moving Higher for Pharming Group (PHAR): Time to Buy? - MSN
Does Pharming Group (PHAR) Have the Potential to Rally 100.91% as Wall Street Analysts Expect? - sharewise.com
FY2025 EPS Estimates for Pharming Group Raised by Analyst - Defense World
Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase After Better-Than-Expected Earnings - Defense World
Pharming Group (NASDAQ:PHAR) Shares Gap Up After Better-Than-Expected Earnings - Defense World
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update - MarketBeat
Pharming Group (PHAR) to Release Earnings on Thursday - Defense World
Pharming Group (NASDAQ:PHAR) Upgraded at Weiss Ratings - Defense World
Pharming Group (NASDAQ:PHAR) Shares Up 9.5%What's Next? - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Down 71.8% in September - MarketBeat
Short Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Increases By 64.2% - MarketBeat
Pharming Group (NASDAQ:PHAR) Stock Price Down 4.6%What's Next? - MarketBeat
Pharming Group (NASDAQ:PHAR) Stock Price Up 7%Still a Buy? - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap UpTime to Buy? - MarketBeat
Pharming Group (NASDAQ:PHAR) Sees Large Volume IncreaseTime to Buy? - MarketBeat
QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study - Finviz
Pharming Group (NASDAQ:PHAR) Shares Gap Up – Still a Buy? - Defense World
Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Pharming Group (NASDAQ:PHAR) Stock Price Down 4.4%What's Next? - MarketBeat
Short Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Increases By 378.6% - MarketBeat
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal - The Globe and Mail
Pharming Group (NASDAQ:PHAR) Stock Price Up 5%Here's Why - MarketBeat
Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus - Zacks Investment Research
Pharming Group appoints Kenneth Lynard as Chief Financial Officer - GlobeNewswire Inc.
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin - The Globe and Mail
Pharming Group (NASDAQ:PHAR) Shares Gap Up – Should You Buy? - Defense World
Wall Street Analysts See a 142.26% Upside in Pharming Group (PHAR): Can the Stock Really Move This High? - ca.finance.yahoo.com
Wall Street Analysts Think Pharming Group (PHAR) Could Surge 145.75%: Read This Before Placing a Bet - Yahoo Finance
Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume on Earnings Beat - Defense World
New Strong Buy Stocks for August 1st - TradingView
Pharming Group (NASDAQ:PHAR) Shares Gap Up After Earnings Beat - Defense World
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):